Inavolisib(CAS: 2060571-02-8)

Inavolisib (CAS: 2060571-02-8) is subject to regulatory guidelines under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), REACH in the European Union, and FDA/EPA requirements for the import, manufacture, and sale of chemical substances in the US and EU. Detailed information on storage, handling, and disposal should be obtained from the respective regulatory bodies.

Inavolisib (CAS: 2060571-02-8) can be synthesized using alternative methods and reagents. Common alternatives include using related phosphoinositide 3-kinase inhibitors, which may offer similar functionalities. However, the choice of alternative will depend on the specific synthesis requirements and desired chemical properties.

The market for Inavolisib (CAS: 2060571-02-8) is driven by ongoing research and development in oncology. Recent trends indicate increasing interest in developing targeted therapies for cancer, and Inavolisib is part of this growing field. Additionally, price trends and demand for this compound are closely tied to advancements in drug development and clinical trials.

Waste containing Inavolisib (CAS: 2060571-02-8) should be collected and disposed of in accordance with local and national regulations. Incineration or professional waste disposal services are recommended. Proper handling and disposal require the use of appropriate personal protective equipment and adherence to environmental protection precautions to minimize the risk of exposure and environmental contamination.